Daniel J. Levangie is an experienced executive and corporate director with senior operating experience in the field of medical devices and in vitro diagnostics. Mr. Levangie is Co-founder and Manager of ATON Partners, a private investment firm, and Chairman, President & CEO of CereVasc, LLC, an early-stage medical device company. From 2013 through January 2017, Mr. Levangie served as President of Insulet Drug Delivery Systems. From 2011 through 2013, Mr. Levangie was Chief Executive Officer of Dune Medical Devices, Inc., and Co-founder and Managing Partner of Constitution Medical Investors, Inc., a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in 2013. Prior to the above, Mr. Levangie held a variety of executive management positions with Cytyc Corporation until the acquisition of Cytyc by Hologic, Inc., in 2007. These positions include Executive Vice President and Chief Operating Officer, Chief Executive Officer and President of Cytyc Health Corporation, Executive Vice President and Chief Commercial Officer and President, Cytyc Surgical Products Division. Prior to joining Cytyc Corporation in 1992, Mr. Levangie held a number of sales, marketing and management positions with Abbott Laboratories. Mr. Levangie is currently a director of CereVasc, LLC, Dune Medical Devices and Renovia, Inc. He previously served as a director of Insulet Corporation, a medical device company, Liposcience, Inc., a diagnostics company, ev3, Inc., a medical device company, and Hologic, Inc., a diagnostic, imaging systems and surgical products company. Mr. Levangie is a member of the Advisory Board of the Barnett Institute of Northeastern University and is a trustee of Excel Charter School, East Boston. Mr. Levangie earned a bachelor's degree in pharmacy from Northeastern University. Levangie brings a wealth of executive, managerial and leadership experience in the healthcare industry to our Board. He has significant director experience from his service on the boards of numerous medical device and biotechnology companies.
What is Daniel J. Levangie's net worth?
The estimated net worth of Daniel J. Levangie is at least $1.36 million as of March 1st, 2024. Mr. Levangie owns 22,975 shares of Exact Sciences stock worth more than $1,358,052 as of September 7th. This net worth evaluation does not reflect any other investments that Mr. Levangie may own. Learn More about Daniel J. Levangie's net worth.
How do I contact Daniel J. Levangie?
Has Daniel J. Levangie been buying or selling shares of Exact Sciences?
Daniel J. Levangie has not been actively trading shares of Exact Sciences during the last quarter. Most recently, Daniel J. Levangie sold 5,000 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $57.50, for a transaction totalling $287,500.00. Following the completion of the sale, the director now directly owns 22,975 shares of the company's stock, valued at $1,321,062.50. Learn More on Daniel J. Levangie's trading history.
Who are Exact Sciences' active insiders?
Exact Sciences' insider roster includes Brian Baranick (Insider), Sarah Condella (SVP), Kevin Conroy (CEO), D. Coward (Insider), Everett Cunningham (Insider), James Doyle (Director), Jeffrey Elliott (CFO), James Herriott (General Counsel), Torsten Hoof (Insider), Daniel Levangie (Director), Graham Lidgard (Insider), Jacob Orville (Insider), and Katherine Zanotti (Director). Learn More on Exact Sciences' active insiders.
Are insiders buying or selling shares of Exact Sciences?
In the last twelve months, insiders at the medical research company sold shares 35 times. They sold a total of 88,497 shares worth more than $5,471,819.36. The most recent insider tranaction occured on May, 1st when Director D Scott Coward sold 67 shares worth more than $4,030.05. Insiders at Exact Sciences own 1.4% of the company.
Learn More about insider trades at Exact Sciences. Information on this page was last updated on 5/1/2024.
